Fisher & Paykel Healthcare Corporation Limited · NZX:FPH

Fisher & Paykel Healthcare — UBS Australian Healthcare Conference 2013

12 slides from Fisher & Paykel Healthcare's conference presentation, June 2013

  1. Slide 1: Fisher & Paykel Healthcare – UBS Australian Healthcare Conference

    Fisher & Paykel Healthcare UBS Australian Healthcare Conference 1 Sydney - June 2013 Investment Highlights • A leader in respiratory and OSA treatment devices • Consistent growth strategy • Estimated US$3.0+ billion and growing market opportunity • High level of innovation • Global presence • Strong

  2. Slide 2: Markets and Products / FY2013 Second Half Highlights

    Markets and Products • Respiratory & Acute Care (RAC) – Heated Humidification – Respiratory Care – Neonatal Care – Surgery • Obstructive Sleep Apnea (OSA) – Masks – Flow Generators – Humidifiers  Consumable and accessory products Revenue by Product Group represent approx. 76% of core product 12 mon

  3. Slide 3: FY13 Operating Results NZ$ / Dividend

    FY13 Operating Results NZ$ FY13 (12 months to 31 March 2013) %Revenue NZ$M PCP CC1 Operating revenue 100% 556.3 +8% +11% Cost of sales 44.7% 248.4 +3% +5% Gross profit 55.3% 307.8 +12% +18% Other income (R&D grant) 2.4 SG&A 27.3% 151.8 +6% +9% R&D 8.2% 45.7 +9% +9% Total operating expenses 35.5% 1

  4. Slide 4: Hospital Cost Breakdown / Lower Care Intensity = Lower Cost

    Hospital Cost Breakdown Utilities, Depreciation Drugs, Devices, Supplies & Food Labour Source: Massachusetts Hospital Association, “An Update to Hospital Costs in Context Report” July 2010 7 Lower Care Intensity = Lower Cost $50,000 $40,000 Mean cost (2008 US$) $30,000 $20,000 $10,000 $0 Outpatient

  5. Slide 5: Respiratory Humidification

    Respiratory Humidification • Normal airway humidification is bypassed or compromised during ventilation or O2 therapy • Mucociliary transport system operates less effectively • Need to deliver gas at physiologically normal levels – 37 oC body core temperature – 44mg/L 100% saturated 9 Respiratory &

  6. Slide 6: Respiratory & Acute Care

    Respiratory & Acute Care • MR850 Respiratory Humidifier System – Invasive ventilation, oxygen therapy and non-invasive ventilation • MR810 Respiratory Humidifier System – Entry level system – Ventilation and oxygen therapy – Optional heated breathing circuit • AIRVO™ Flow Generator/Humidifier – Opti

  7. Slide 7: Respiratory & Acute Care Update / Obstructive Sleep Apnea

    Respiratory & Acute Care Update H2 FY2013 • Operating revenue growth – NZ$ +13% – Constant currency +18% • New applications consumables revenue growth (NIV, Optiflow™, AIRVO™, Surgical) – NZ$ +32% – Constant currency +38% – New applications, 38% of RAC consumables revenue • New products roll-out – E

  8. Slide 8: Revolutionary New Masks

    Revolutionary New Masks • Comfortable • Easy to fit • Efficient • Nasal Pillows – F&P Pilairo™ • Nasal – F&P Eson™ • Full Face – F&P Simplus™ 15 + • Stylish, Smart + Simplified • Efficiently integrates with InfoUSB™ and InfoSmart™ Web • Responsive pressure relief - SensAwake™ • ThermoSmart™ Humidifi

  9. Slide 9: Efficient Compliance Reporting / Obstructive Sleep Apnea Update

    Efficient Compliance Reporting 17 Obstructive Sleep Apnea Update H2 FY2013 • Operating revenue growth – NZ$ +6% – Constant currency +10% • Mask revenue growth – Constant currency +16% • New products roll-out – F&P Pilairo™ – F&P Eson™ – F&P Simplus™ – F&P ICON™+ 18

  10. Slide 10: Research & Development / New Products

    Research & Development • 8.2% of operating revenue, NZ$45.7M1 • Product pipeline includes: – Humidifier controllers – Masks – Respiratory consumables – Flow generators – Compliance monitoring solutions • 107 US patents, 159 US pending, 442 ROW, 260 ROW pending1 1 at 31 March 2013 19 New Products • P

  11. Slide 11: Manufacturing & Operations / Global Presence

    Manufacturing & Operations • Vertically integrated – COGs improvements; Mexico, Lean, supply chain • Ample capacity to grow Auckland, New Zealand Tijuana, Mexico – Two buildings: 51,000m² / – 18,000m2/200,000ft2 550,000ft² total – Consumables capacity ramping up – 31,000m2 building 3 completed Novem

  12. Slide 12: Consistent Growth Strategy

    Consistent Growth Strategy • Experts in humidification, respiratory care, and obstructive sleep apnea • Provide innovative devices which can improve patient care and outcomes • Continuous product improvement • More devices for each patient • Serve more patient groups – Invasive ventilation, NIV, oxy

Fisher & Paykel Healthcare — UBS Australian Healthcare Conference 2013 on 6ix